Download PDF
Psychiatr Prax 2006; 33: 32-39
DOI: 10.1055/s-2005-867019
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Pharmakologische Therapie manisch-depressiver Mischzustände

Pharmacotherapy of Manic-Depressive Mixed StatesStephanie  Krüger1 , Trevor  Young2 , Peter  Bräunig3
  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl-Gustav Carus, Dresden
  • 2Center for Addiction and Mental Health, University of Toronto, Canada
  • 3Klinik für Psychiatrie und Psychotherapie, Vivantes Humboldt-Klinikum Berlin
Further Information

Publication History

Publication Date:
01 March 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Manisch-depressive Mischzustände kommen in 40 % aller akuten bipolaren Episoden vor. Es handelt sich um komplexe, schwer zu behandelnde klinische Bilder. In diesem Beitrag soll ein Überblick über die Literatur zur Therapie der Mischzustände gegeben werden. Methode: Die Literatur wurde anhand von Medline-, Embase- und dem Cochrane-Controlled-Trials-Register-Suche identifiziert. Stichwörter waren „mixed mania”, „mixed state/(s)”, „mixed episode/(s)”, „treatment”, „therapy”, „study” und „trial”. Ergebnisse: Es fanden sich sehr wenige doppelblinde, plazebokontrollierte Studien, die sich speziell mit der Therapie manisch-depressiver Mischzustände beschäftigen. Stattdessen sind Patienten mit Mischzuständen oftmals eine Untergruppe der untersuchten Gesamtkohorte. Die verfügbaren Daten zeigen, dass akute Mischzustände nicht günstig auf Lithium ansprechen. Stattdessen sind Valproat und Olanzapin die Medikamente der ersten Wahl. Antidepressiva sollten vermieden werden, weil sie das intraepisodische Switching dieser Episoden verstärken können. Lamotrigin kann bei Mischzuständen mit überwiegend depressiven Symptomen eingesetzt werden. Schlussfolgerungen: Es sind mehr Studien nötig, die sich speziell mit der Therapie manisch-depressiver Mischzustände befassen. Behandlungsempfehlungen können nur vorläufig sein, weil die Datenlage eine definitive Therapieempfehlung zum jetzigen Zeitpunkt nicht zulässt.

Abstract

Objective: Mixed episodes comprise up to 40 % of acute bipolar admissions. They are difficult-to-treat, complex clinical pictures. This review provides an overview of the available literature on the pharmacotherapy of manic-depressive mixed states and suggests treatment options. Method: Literature was identified by searches in Medline, Embase and the Cochrane Controlled Trials Register. Studies were considered relevant if they contained the keywords mixed mania, mixed state (s), mixed episode (s), treatment, therapy, study or trial. Results: Overall, there were very few double-blind, placebo-controlled studies specifically designed to treat manic-depressive mixed states. Rather, patients with mixed states comprised a subgroup of the examined patient cohorts. Nevertheless, the data show that acute mixed states do not respond favourably to lithium. Instead, valproate and olanzapine are drugs of first choice. Carbamazepine may play a role in the prevention of mixed states. Antidepressants should be avoided, because they may worsen intraepisodic mood lability. Lamotrigine may be useful in treating mixed states with predominantly depressive symptoms. Conclusions: More treatment studies specifically designed to treat the complex clinical picture of mixed states are clearly needed. Current treatment recommendations for clinical practice based on the available literature can only target selected aspects of these episodes.

Literatur

  • 1 Secunda S K, Swann A, Katz M M, Koslow S H, Croughan J, Chang S. Diagnosis and treatment of mixed mania.  Am J Psychiatry. 1987;  144 (1) 96-98
    PubMedGoogle Scholar
  • 2 Cohen S, Khan A, Robison J. Significance of mixed features in acute mania.  Compr Psychiatry. 1988;  29 (4) 421-426
    CrossrefPubMedGoogle Scholar
  • 3 Krüger S, Cooke R G, Spegg C, Bräunig P. Relevance of the catatonic syndrome to the mixed manic episode.  J Affect Disord. 2003;  74 (3) 279-285
    CrossrefPubMedGoogle Scholar
  • 4 Goldberg J F, Garno J L, Leon A C, Kocsis J H, Portera L. Association of recurrent suicidal ideation with non-remission from acute mixed mania.  Am J Psychiatry. 1998;  155 (12) 1753-1755
    PubMedGoogle Scholar
  • 5 Freeman M P, McElroy S L. Clinical picture and etiological models of mixed states.  Psychiatr Clin North Am. 1999;  22 (3) 535-546
    CrossrefPubMedGoogle Scholar
  • 6 Perugi G, Akiskal H S, Micheli C, Musetti L, Paiano A, Quilici C, Rossi L, Cassano G B. Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases.  J Affect Disord. 1997;  43 (3) 169-180
    PubMedGoogle Scholar
  • 7 Cole A J, Scott J, Ferrier I N, Eccleston D. Patterns of treatment resistance in bipolar affective disorder.  Acta Psychiatr Scand. 1993;  88 (2) 121-123
    PubMedGoogle Scholar
  • 8 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. 4th edition ed. Washington, DC; American Psychiatric Press 1996
    Google Scholar
  • 9 World Health Organization .Internationale Klassifikation psychischer Störungen, ICD 10. Bern, Switzerland; Hans Huber 1994
    Google Scholar
  • 10 Freeman T W, Clothier J L, Pazzaglia P, Lesem M D, Swann A C. A double-blind comparison of valproate and lithium in the treatment of acute mania.  Am J Psychiatry. 1992;  149 (1) 108-111
    PubMedGoogle Scholar
  • 11 Clothier J L, Swann A C, Freeman T W. Dysphoric mania.  J Clin Psychopharmacol. 1992;  12 (1, Suppl) 13S-16S
    PubMedGoogle Scholar
  • 12 Swann A C, Secunda S K, Katz M M, Koslow S H, Maas J W, Chuang S, Robins E. Lithium treatment of mania: Clinical characteristics, specificity of symptom change, and outcome.  Psychiatry Research. 1986;  18 127-141
    CrossrefPubMedGoogle Scholar
  • 13 Goldberg J F, Garno J L, Leon A C, Kocsis J H, Portera L. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients [published erratum appears in J Clin Psychiatry 1998; 59 (6): 320].  J Clin Psychiatry. 1998;  59 (4) 151-158
    PubMedGoogle Scholar
  • 14 Frye M A, Ketter T A, Leverich G S, Huggins T, Lantz C, Denicoff K D, Post R M. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.  J Clin Psychiatry. 2000;  61 (1) 9-15
    PubMedGoogle Scholar
  • 15 Frye M A, Altshuler L L, Szuba M P, Finch N N, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay.  J Clin Psychiatry. 1996;  57 (1) 17-21
    PubMedGoogle Scholar
  • 16 McElroy S L, Keck P EJ, Pope H GJ, Hudson J I. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines.  J Clin Psychopharmacol. 1992;  12 (1 Suppl) 42S-52S
    PubMedGoogle Scholar
  • 17 Overall J E, Gorham D R. The Brief Psychiatric Rating Scale.  Psychol Rep. 1962;  10 799-812
    CrossrefPubMedGoogle Scholar
  • 18 Endicott J, Spitzer R L, Fleiss R L, Cohen J. The global assessment of functioning scale: A procedure for measuring overall severity of psychiatric disturbance.  Arch Gen Psychiatry. 1976;  33 766-771
    PubMedGoogle Scholar
  • 19 McFarland B H, Miller M R, Straumfjord A A. Valproate use in the older manic patient.  J Clin Psychiatry. 1990;  51 479-481
    PubMedGoogle Scholar
  • 20 Calabrese J R, Markovitz P J, Kimmel S E, Wagner S C. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients.  J Clin Psychopharmacol. 1992;  12 (1 Suppl) 53S-56S
    PubMedGoogle Scholar
  • 21 Ballenger J C, Post R M. Carbamazepine in manic-depressive illness: a new treatment.  Am J Psychiatry. 1980;  137 782-790
    CrossrefPubMedGoogle Scholar
  • 22 Bowden C L. Carbamazepine in bipolar disorder. In: Goodnick PJ (ed) Predictors of treatment response in mood disorders. Clinical Practice, No 34. Washington, DC, USA; American Psychiatric Press 1996: 119-132
    Google Scholar
  • 23 Post R M, Rubinow D R, Uhde T W, Roy-Burne P P, Linnoila M, Rosoff A, Cowdry R. Dysphoric mania.  Arch Gen Psychiatry. 1989;  46 353-358
    PubMedGoogle Scholar
  • 24 Ketter T A, Kalali A H, Weisler S SG. A multicenter, open label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes.  J Clin Psychiatry. 2004;  65 668-673
    PubMedGoogle Scholar
  • 25 Hamilton M. A rating scale for depression.  J Neuro Neurosurg Psychiatr. 1960;  23 56-62
    CrossrefPubMedGoogle Scholar
  • 26 Young R, Biggs J, Meyer D. A rating scale for mania.  Br J Psychiatr. 1978;  133 429-435
    CrossrefPubMedGoogle Scholar
  • 27 Barbosa L, Berk M, Forster M A. Double-blind, placebo-controlled trial of augmentation with lamotrogine or placebo in patients concomitantly treated with fluoxetine for resistant depression.  J Clin Psychiatry. 2003;  64 (4) 403-407
    PubMedGoogle Scholar
  • 28 Bowden C L, Calabrese J R, McElroy S L, Rhodes L J, Keck Jr P E, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E, Zhou J. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder.  Biol Psychiatry. 1999;  45 (8) 953-958
    PubMedGoogle Scholar
  • 29 Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.  J Clin Psychiatry. 1999;  60 (2) 79-88
    CrossrefPubMedGoogle Scholar
  • 30 Calabrese J R, Bowden C L, McElroy S L, Cookson J, Andersen J, Keck Jr P E, Rhodes L, Bolden-Watson C, Zhou J. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder.  Am J Psychiatry. 1999;  156 (7) 1019-1023
    PubMedGoogle Scholar
  • 31 Gidal B E, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy.  Epilepsy Res. 2003;  57 (2 - 3) 85-93
    CrossrefPubMedGoogle Scholar
  • 32 Pande A C, Crockatt J G, Janney C A, Werth J L, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.  Bipolar Disord. 2000;  2 (3) 249-255
    CrossrefPubMedGoogle Scholar
  • 33 Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Aksikal H. Clinical experience using adjunctive gabapentin in treatment resistant bipolar mixed states.  Pharmacopsychiat. 1999;  32 (4) 136-141
    PubMedGoogle Scholar
  • 34 Sokolski K, Green C, Maris D, DeMet E. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology.  Ann Clin Psychiatry. 1999;  11 (4) 217-222
    CrossrefPubMedGoogle Scholar
  • 35 Larkin J G, McKee P J, Forrest G, Beastall G H, Park B K, Lowrie L I, Lloyd P, Brody M J. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.  Br J Clin Pharmacol. 1991;  31 (1) 65-71
    PubMedGoogle Scholar
  • 36 Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano G B. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode.  J Affect Disord. 2004;  79 (1 - 3) 273-277
    CrossrefPubMedGoogle Scholar
  • 37 Ghaemi S N, Berv D A, Klugman J, Rosenquist K J, Hsu D J. Oxcarbazepine treatment of bipolar disorder.  J Clin Psychiatry. 2003;  64 (8) 943-945
    PubMedGoogle Scholar
  • 38 Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A, Cadevall J, Garcia-Castrillon J, Lusilla P, Arrufat F. Use of topiramate in treatment-resistant bipolar spectrum disorders.  J Clin Psychopharmacol. 2002;  22 (4) 431-435
    CrossrefPubMedGoogle Scholar
  • 39 McElroy S L, Suppes T, Keck P E, Frye M A, Denicoff K D, Altshuler L L, Brown E S, Nolen W A, Kupka R W, Rochussen J, Leverich G S, Post R M. Open-label adjunctive topiramate in the treatment of bipolar disorders.  Biol Psychiatry. 2000;  47 (12) 1025-1033
    CrossrefPubMedGoogle Scholar
  • 40 Chengappa K N, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar J S. Topiramate as add-on treatment for patients with bipolar mania.  Bipolar Disord. 1999;  1 (1) 42-53
    CrossrefPubMedGoogle Scholar
  • 41 Zarate Jr C A, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients.  Am J Psychiatry. 2004;  161 (1) 169-171
    CrossrefPubMedGoogle Scholar
  • 42 Hirschfeld R M. The efficacy of atypical antispychotics in bipolar disorders.  J Clin Psychiatry. 2003;  64 (8) 15-21
    PubMedGoogle Scholar
  • 43 Suppes T, McElroy S L, Gilbert G, Dessain E C, Cole J O. Clozapine in the treatment of dysphoric mania.  Biol Psychiatr. 1992;  32 (3) 270-280
    CrossrefPubMedGoogle Scholar
  • 44 Zarate Jr C A, Tohen M, Baldessarini R J. Clozapine therapy in severe mood disorders.  J Clin Psychiatry. 1995;  56 108-112
    PubMedGoogle Scholar
  • 45 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G, Petty F, Centorrino F, Wang R, Grundy S L, Greaney M G, Jacobs T G, David S R, Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.  Am J Psychiatry. 1999;  156 (5) 702-709
    PubMedGoogle Scholar
  • 46 Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson G D, Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group.  Arch Gen Psychiatry. 2000;  57 (9) 841-849
    CrossrefPubMedGoogle Scholar
  • 47 Tohen M, Chengappa K N, Suppes T, Zarate Jr C A, Calabrese J R, Bowden C L, Sachs G S, Kupfer D J, Baker R W, Risser R C, Keeter E L, Feldman P D, Tollefson G D, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.  Arch Gen Psychiatry. 2002;  59 (1) 62-69
    CrossrefPubMedGoogle Scholar
  • 48 Tohen M, Ketter T A, Zarate C A, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh L M, Risser R C, Brown E, Baker R W. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.  Am J Psychiatry. 2003;  160 (7) 1263-1271
    CrossrefPubMedGoogle Scholar
  • 49 Baker R W, Tohen M, Fawcett J, Risser R C, Schuh L M, Brown E, Stauffer V L, Shao L, Tollefson G D. Acute dysphoric mania: treatment response to olanzapine versus placebo.  J Clin Psychopharmacol. 2003;  23 (2) 132-137
    CrossrefPubMedGoogle Scholar
  • 50 Ketter T A, Winsberg M E, DeGolia S G, Dunai M, Tate D L, Strong C M. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.  J Clin Psychiatry. 1998;  59 (2) 83-85
    PubMedGoogle Scholar
  • 51 Zullino D, Baumann P. Olanzapine for mixed episodes of bipolar disorder.  J Psychopharmacol. 1999;  13 (2) 198
    PubMedGoogle Scholar
  • 52 Sharma V, Pistor L. Treatment of bipolar mixed state with olanzapine.  J Psychiatry Neurosci. 1999;  24 (1) 40-44
    PubMedGoogle Scholar
  • 53 Sachs G S, Grossman F, Ghaemi S N, Okamoto A, Bowden C L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.  Am J Psychiatry. 2002;  159 1146-1154
    CrossrefPubMedGoogle Scholar
  • 54 Yatham L N, Grossman F, Augustyns I, Vieta E, Ravindran A V. Mood stabilisers plus risperidone or placebo in the treatment of acute mania.  Br J Psychiatry. 2003;  182 141-147
    CrossrefPubMedGoogle Scholar
  • 55 Benabarre A, Vieta E, Colom F, Martinez A, Reinares M, Corbella B. Treatment of mixed mania with risperidone and mood stabilizers.  Can J Psychiatry. 2001;  46 (9) 866-867
    PubMedGoogle Scholar
  • 56 Vieta E, Herraiz M, Parramon G, Goikolea J M, Fernandez A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain.  J Affect Disord. 2002;  72 (1) 15-19
    CrossrefPubMedGoogle Scholar
  • 57 DelBello M P, Schwiers M L, Rosenberg H L, Strakowski S M. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.  J Am Acad Child Adolesc Psychiatry. 2002;  41 (10) 1216-1223
    PubMedGoogle Scholar
  • 58 Vieta E, Parramon G, Padrell E, Nieto E, Martinez-Aran A, Corbella B, Colom F, Reinares M, Goikolea J M, Torrent C. Quetiapine in the treatment of rapid cycling bipolar disorder.  Bipolar Disord. 2002;  4 (5) 335-340
    CrossrefPubMedGoogle Scholar
  • 59 Zarate Jr C A, Rothschild A, Fletcher K E, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders.  J Clin Psychiatry. 2000;  61 (3) 185-189
    PubMedGoogle Scholar
  • 60 Keck Jr P E, Versiani M, Potkin S, West S A, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.  Am J Psychiatry. 2003;  160 (4) 741-748
    CrossrefPubMedGoogle Scholar
  • 61 Keck Jr P E, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.  Am J Psychiatry. 2003;  160 (9) 1651-1658
    CrossrefPubMedGoogle Scholar
  • 62 Post R M, Leverich G S, Nolen W A, Kupka R W, Altshuler L L, Frye M A, Suppes T, McElroy S, Keck P, Grunze H, Walden J. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.  Bipolar Disord. 2003;  5 (6) 396-406
    CrossrefPubMedGoogle Scholar
  • 63 Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder.  J Clin Psychiatry. 2002;  63, Suppl 10 23-28
    PubMedGoogle Scholar
  • 64 Post R M, Altshuler L L, Frye M A, Suppes T, Rush A J, Keck Jr P E, McElroy S L, Denicoff K D, Leverich G S, Kupka R, Nolen W A. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers.  Bipolar Disord. 2001;  3 (5) 259-265
    PubMedGoogle Scholar
  • 65 Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants.  Br J Psychiatry. 1994;  164 (4) 549-550
    PubMedGoogle Scholar
  • 66 Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: identification of risk factors.  J Clin Psychiatry. 2001;  62 (4) 249-255
    CrossrefPubMedGoogle Scholar
  • 67 Ghaemi S N, Rosenquist K J, Ko J Y, Baldassano C F, Kontos N J, Baldessarini R J. Antidepressant treatment in bipolar versus unipolar depression.  Am J Psychiatry. 2004;  161 (1) 163-165
    CrossrefPubMedGoogle Scholar
  • 68 Bauer M S, Callahan A M, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell B J. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs.  J Clin Psychiatry. 1999;  60 (1) 9-21
    PubMedGoogle Scholar
  • 69 Sachs G S, Printz D J, Kahn D A, Carpenter D, Docherty J P. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.  Postgrad Med. 2000;  Spec No 1-104
    PubMedGoogle Scholar
  • 70 Sachs G S. Decision tree for the treatment of bipolar disorder.  J Clin Psychiatry. 2003;  64, Suppl 8 35-40
    PubMedGoogle Scholar
  • 71 Suppes T, Dennehy E B, Swann A C, Bowden C L, Calabrese J R, Hirschfeld R M, Keck Jr P E, Sachs G S, Crismon M L, Toprac M G, Shon S P. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.  J Clin Psychiatry. 2002;  63 (4) 288-299
    PubMedGoogle Scholar
  • 72 Goodwin G M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology.  J Psychopharmacol. 2003;  17 (2) 149-173
    CrossrefPubMedGoogle Scholar
  • 73 Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R W, Vieta E, Möller H J. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania.  World J Biol Psychiatry. 2003;  4 (1) 5-13
    PubMedGoogle Scholar
  • 74 Grunze H, Walden J, Dittmann S, Berger M, Bergmann A, Braunig P, Dose M, Emrich H M, Gastpar M, Greil W, Krüger S, Möller H J, Übelhack R. Psychopharmacotherapy of bipolar affective diseases.  Nervenarzt. 2002;  73 (1) 4-17
    CrossrefPubMedGoogle Scholar
  • 75 Licht R W, Vestergaard P, Kessing L V, Larsen J K, Thomsen P H. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark.  Acta Psychiatr Scand Suppl. 2003;  (419) 1-22
    PubMedGoogle Scholar
  • 76 American Psychiatric Association . Practice guideline for the treatment of patients with bipolar disorder (Revision).  Am J Psychiatry. 2002;  159 (4 Suppl) 1-50
    CrossrefPubMedGoogle Scholar
  • 77 Hirschfeld R M, Baker J D, Wozniak P, Tracy K, Sommerville K W. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.  J Clin Psychiatry. 2003;  64 (7) 841-846
    CrossrefPubMedGoogle Scholar
  • 78 Oluboka O J, Bird D C, Kutcher S, Kusumakar V. A pilot study of loading versus titration of valproate in the treatment of acute mania.  Bipolar Disord. 2002;  4 (5) 341-345
    CrossrefPubMedGoogle Scholar
  • 79 Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.  J Clin Psychiatry. 2004;  65, Suppl 5 7-12
    PubMedGoogle Scholar
  • 80 Easton M S, Janicak P G. Benzodiazepines (BZ) for the management of psychosis.  Psychiatr Med. 1991;  9 (1) 25-36
    PubMedGoogle Scholar
  • 81 Menza M A, Harris D. Benzodiazepines and catatonia. An overview.  Biol Psychiatry. 1989;  (26) 842-846
    CrossrefPubMedGoogle Scholar

Priv.-Doz. Dr. med. Stephanie Krüger

Klinik und Poliklinik für Psychiatrie und Psychotherapie · Universitätsklinikum Carl-Gustav Carus

Fetscherstraße 74

01307 Dresden

Email: stephanie.krueger@uniklinikum-dresden.de

      >